Skip to main content
Viatris8-K: Acquisition announced

Viatris to Acquire Pacira BioSciences for $36.50 Per Share or $1.65 Billion in Cash

Source: Autobound Signal API · 76 signals tracked for Viatris · updated

Get Viatris' live signals in Claude or ChatGPT, or by API

AskWhat changed at Viatris this week? Use Autobound signals for viatris.com.

What happened

Viatris entered into a definitive agreement to acquire all outstanding common shares of Pacira BioSciences for an aggregate equity value of $1.65 billion, with closing expected by the end of November 2026.

Source

SEC EDGARNov 5, 2026

Current report (Form 8-K)

Viatris 8-K

Filing excerpt

In October, the Company and Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, announced that they entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.

sec.gov/Archives/edgar/data/1792044/000179204426000053/vtrs-20261105.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
8-K: Acquisition announced

What this signalsIntegration work after a deal often opens needs for new systems and services.

Form
8-K
Fiscal year end
11/05
Filed
Nov 5, 2026

More 8-K signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$1.6B (aggregate equity value for the acquisition of Pacira BioSciences)

Details

CIK
1792044
Accession number
0001792044-26-000053
Timeframe
Current quarter
Filing year
2026
Why it matters
Integration needs coming
Signal category
Strategic

Extraction

Confidence
High
Relevance
95%
Sentiment
Positive
Detected
Nov 10, 2026
signal_type
sec-8k
signal_subtype
acquisitionAnnounced

Use this data

Get every 8-K signal for Viatris and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/1dd85072-97cc-4eb0-b0cd-8d72740402a5 returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.

{
  "signal_id": "1dd85072-97cc-4eb0-b0cd-8d72740402a5",
  "signal_type": "sec-8k",
  "signal_subtype": "acquisitionAnnounced",
  "detected_at": "2026-11-10T07:04:16.283+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "detail": "Viatris entered into a definitive agreement to acquire all outstanding common shares of Pacira BioSciences for an aggregate equity value of $1.65 billion, with closing expected by the end of November 2026. This large-scale transaction creates immediate integration, M&A advisory, regulatory, and healthcare commercialization vendor opportunities.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "aggregate equity value for the acquisition of Pacira BioSciences",
      "dollar_millions": 1650
    },
    "summary": "Viatris to Acquire Pacira BioSciences for $36.50 Per Share or $1.65 Billion in Cash",
    "excerpts": "In October, the Company and Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, announced that they entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.",
    "relevance": 0.95,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/vtrs-20261105.htm",
    "filing_date": "2026-11-05",
    "filing_year": 2026,
    "fiscal_year_end": "11/05",
    "sales_relevance": "Integration needs coming",
    "signal_category": "strategic"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.